George Favvas knows what it takes to make a telehealth business profitable. He spent the better part of a decade building Circle Medical into what the company reports as a $100-million-plus revenue operation—one of the rare digital health ventures that actually turned a profit without burning through hundreds of millions in venture capital. So when he walked away from that success to start over, people in the tight-knit world of healthcare technology took notice.
What came next was Clara.
Launched on May 14, 2026, with $12 million in pre-seed funding from Y Combinator and A.Capital, Clara is something the founders describe as an "AI-powered primary care practice." It's a carefully chosen phrase. The service itself is explicit about what it is not: "Clara is an AI-powered doctor, not a licensed physician," the website declares. This isn't semantic hedging—it's the entire business model.
Here's how it works: Clara's artificial intelligence ingests your complete medical history from more than 150,000 hospitals, labs, and pharmacies. It analyzes patterns across years of data points, flags anomalies, and drafts clinical recommendations. Want a prescription refill? The AI drafts it. Need lab work ordered? The system generates the request. But nothing—absolutely nothing—moves forward without a licensed clinician in your state reviewing and signing off on the recommendation.
It's a physician-in-the-loop model, a deliberately hybrid approach that threads the needle between full automation and traditional telehealth. The founders believe it's the architecture that will define the next era of primary care. Whether they're right is a $12 million question.
The Team That's Been There Before
Favvas didn't build Clara alone. He brought along two cofounders from Circle Medical—Caitlin Swift, a nurse practitioner who ran clinical operations through nearly one million telehealth encounters annually, and Zeeshan Ahmed, whose design background spans Instagram retail ads at Meta and work on Careem. Together, they oversee a nine-person team as of mid-May, though that number could shift quickly. The company is actively hiring founding engineers, the kind who show up when the product is raw and the mission is ambitious.
The medical leadership they recruited carries serious weight. Brendan Levy, who joined as Chief Medical Officer, founded HeyDoctor, sold it to GoodRx, and served in senior medical roles at Hims & Hers and Lemonaid Health. Claudia Tucker, now VP of Government & Regulatory Affairs, spent years at Teladoc Health navigating the state-by-state expansion of telehealth during COVID. These are not people experimenting with healthcare for the first time. They've seen what breaks under regulatory pressure. They know where the landmines are buried.
That pedigree matters more than it might seem. Digital health is littered with well-funded startups that underestimated the complexity of multi-state licensure, compliance infrastructure, and the sheer operational grind of healthcare delivery. Circle Medical, by contrast, scaled to profitability on just $12 million in primary capital in its earlier years—a rarity in an industry where companies routinely raise ten times that amount to reach the same milestones. The founders aren't building on speculation; they're building on scar tissue.
What Clara Actually Does
The product experience begins with data. Lots of it. Clara claims to pull medical records through health information exchange networks—CommonWell, Carequality, eHealth Exchange—accessing more than 150,000 hospitals, labs, and pharmacies. Patients can layer in wearable data and upload lab results directly. The AI reads it all, flagging inconsistencies, tracking trends, and assembling a longitudinal view of your health.
Then it drafts. A prescription for hypertension medication. A lab order for a lipid panel. A referral to a cardiologist. The recommendations show up in the interface, but they sit there, waiting, until a licensed clinician reviews and approves them. That clinician is licensed in the patient's state—a regulatory requirement Clara navigates through multiple affiliated professional entities structured for state-by-state practice.
Clinical responses typically arrive within 24 hours during business hours: Monday through Friday, 8 a.m. to 5 p.m. The platform itself is accessible around the clock for messaging, but Clara is explicit about what it's not designed for. This isn't an emergency service. Controlled substances are off-limits. If you're in acute distress, you're directed elsewhere.
The scope of conditions treated is broad, though. Cardiometabolic issues—hypertension, high cholesterol, type 2 diabetes. Acute infections like UTIs and sinus problems. Preventive care screenings. Mental health assessments using PHQ-9 and GAD-7 tools. Hormonal conditions including perimenopause, menopause, and hypothyroidism. Weight management with FDA-approved GLP-1 medications, the class of drugs that's become a cultural phenomenon in its own right.
Clara is structured as cash-pay memberships, which simplifies the business model considerably but narrows the addressable market to those willing—or able—to pay out of pocket. HSA and FSA funds can be used, and prescriptions or lab work ordered through Clara may be covered by insurance through standard pharmacy and lab channels. But the membership itself? That's on you.
The Pricing Bet
Three tiers. The Basic plan runs $25 a month—messaging with the AI, clinician oversight, prescriptions, lab orders. Standard is $50 monthly and includes a 74-biomarker lab panel. Concierge costs $150 per month with 107 biomarker tests. (Some landing pages list 108, a small inconsistency in the site copy that suggests the product is still being tweaked in real time.)
The pricing sits below many concierge medical practices but well above traditional primary care copays for those with insurance. It's also substantially more expensive than Lotus Health, a competitor offering free visits funded by venture capital—a strategy that works until it doesn't. Clara's approach suggests the founders believe proven operators can build a sustainable business on cash-pay memberships without relying on employer contracts or the labyrinthine complexity of insurance reimbursement.
Whether that thesis holds depends on finding enough customers willing to pay for something that occupies an odd space: more comprehensive than a symptom checker, less personal than a traditional doctor's visit, and legally distinct from both. The market for that product may be sizable, or it may be a niche. The founders have a theory. Now they get to test it.
Longevity, With a Capital L
Clara's stated mission is audacious: "add one billion years of healthspan to humanity." It's the kind of declaration that reads as Silicon Valley hyperbole until you realize it's baked directly into the product design.
The Concierge tier emphasizes longitudinal biomarker tracking—monitoring ApoB trajectories over time, watching cardiovascular risk markers shift, layering in wearable data to spot patterns a human clinician might miss across months or years of data points. A licensed clinician still reviews and interprets the findings, but the AI does the analytical heavy lifting, parsing trends in ways that would be impractical for a physician juggling dozens of patients.
The longevity framing is both marketing and strategy. It positions Clara as something beyond episodic sick care—a tool for the growing cohort of consumers willing to pay cash for biomarker tracking, supplement protocols, and data-driven health optimization. Whether that market is large enough to support venture-scale growth remains an open question. But the team's track record suggests they didn't make the bet lightly.
A Crowded, Chaotic Landscape
Clara enters a market where AI health tools are proliferating rapidly, though few companies are positioning themselves as full primary care replacements. Lotus Health reportedly raised $35 million earlier this year with a similar "AI doctor" framing—licensed in 50 states, malpractice coverage, free patient visits. Amazon rolled out an AI assistant for One Medical members. Microsoft announced Copilot Health. Google's AI Health Coach, priced at $9.99 per month, is positioned as wellness coaching rather than licensed medical care.
K Health has been operating in the clinical AI space for years, publishing studies on AI-generated recommendations and partnering with health systems to streamline chart prep for primary care physicians. The model has proven viable in pockets but hasn't reshaped primary care delivery at scale.
The macro backdrop is shifting, too, though it's hard to say in which direction. Federal programs exploring AI-driven care models are expanding. State medical boards are grappling with how to regulate AI-mediated clinical workflows. And the business fundamentals of primary care remain punishing—Carbon Health filed for Chapter 11 protection earlier this year, a stark reminder that digital health unit economics are unforgiving even in favorable market conditions.
Clara's differentiation rests on a few pillars: the team's operational track record, the depth of data ingestion and longitudinal analysis, and a hybrid model where AI handles reasoning while clinicians retain ultimate medical authority. Whether that's enough to build something durable in such a crowded field is precisely what investors just wagered $12 million on.
What Happens Next
The funding round included participation from Liquid 2 Ventures (Joe Montana and Matthew Mulvey), SV Angel, and a long roster of angel investors and operators—Tim Abbott, Immad Akhund, Vinny Lingham, Jude Gomilla, Kevin Hartz, Brian Pokorny, Dan Burleigh. Y Combinator, which accepted Clara into its most recent batch, co-led the round with A.Capital.
Media coverage has been limited so far. A Launch post on Y Combinator's platform. The company's blog. An early write-up from iatroX, a clinician-authored blog that praised Clara's "AI-native primary care" positioning as something distinct from symptom checkers or ambient clinical scribes. The major tech and health trade publications haven't weighed in yet, which could mean they're watching and waiting—or that the launch is still too early to draw conclusions.
The company's claim of 50-state licensure is central to its pitch, though it hasn't been independently verified through state medical board rosters. Clara lists multiple affiliated professional corporations on its informed consent forms, a structure designed for multi-state telehealth practice. For an audience of healthcare founders and healthtech investors, the regulatory execution will be as critical to watch as the product itself. Perhaps more so.
The broader question hanging over Clara—and the entire AI-in-medicine wave—is whether patients, regulators, and the medical establishment are prepared for AI-first care models. Favvas and his cofounders built Circle Medical in an era when telehealth itself was novel, when the idea of seeing a doctor over video was still being normalized. They're building Clara in an era when artificial intelligence is both ubiquitous and deeply contested in healthcare settings, where enthusiasm and skepticism coexist in roughly equal measure.
The difference this time? The founders already know what it takes to scale a healthcare business profitably. Whether that matters more than the technology risk—whether operational experience can compensate for regulatory uncertainty and market ambiguity—is the story still being written. And it's one worth watching closely.
